Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells

Thomas W. Grunt, Renate Wagner, Michael Grusch, Walter Berger, Christian F. Singer, Brigitte Marian, Christoph C. Zielinski, Ruth Lupu

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Fatty acid synthase (FASN) represents a metabolic oncogene. It produces phospholipids for membrane microdomains that accommodate receptor tyrosine kinases including Epidermal Growth Factor-Receptor (EGFR, ErbB1) and ErbB2 (HER2/neu). FASN and ErbBs are overexpressed in ovarian cancer. We examined the effect of FASN and ErbB inhibition on A2780 and SKOV3 ovarian cancer cells. Growth assays reveal that FASN inhibitor C75 sensitizes tumor cells against anti-ErbB drugs (pelitinib [EKB-569], canertinib [CI-1033], erlotinib, cetuximab, matuzumab, trastuzumab) suggesting FASN/ErbB cooperation. qRT-PCR and Western blotting revealed that C75 represses FASN, EGFR, ErbB2, and AKT suggesting that FASN-induced membrane microdomains accommodate/stabilize ErbBs and facilitate AKT recruitment/activation. Our data indicate that AKT is crucial for ErbB/FASN interaction, AKT cross-inhibits ERK and feeds loops that boost FASN and EGFR transcription, and EGFR and ErbB2 must be co-silenced for maximal FASN downregulation. Taken together, interference with FASN and ErbB abrogates their oncogenicity and should be exploited for ovarian cancer treatment.

Original languageEnglish (US)
Pages (from-to)454-459
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume385
Issue number3
DOIs
StatePublished - Jul 31 2009

Fingerprint

Fatty Acid Synthases
Ovarian Neoplasms
Cells
Membrane Microdomains
Membranes
Oncology
Receptor Protein-Tyrosine Kinases
Transcription
Oncogenes
Epidermal Growth Factor Receptor
Tumors
Assays
Phospholipids
Down-Regulation
Western Blotting
Chemical activation

Keywords

  • Crosstalk
  • EGFR
  • EGFR antibody
  • ErbB/HER
  • ErbB2 antibody
  • ErbB2/HER2
  • Fatty acid synthase
  • Ovarian cancer
  • Receptor tyrosine kinase
  • Small-molecule tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. / Grunt, Thomas W.; Wagner, Renate; Grusch, Michael; Berger, Walter; Singer, Christian F.; Marian, Brigitte; Zielinski, Christoph C.; Lupu, Ruth.

In: Biochemical and Biophysical Research Communications, Vol. 385, No. 3, 31.07.2009, p. 454-459.

Research output: Contribution to journalArticle

Grunt, TW, Wagner, R, Grusch, M, Berger, W, Singer, CF, Marian, B, Zielinski, CC & Lupu, R 2009, 'Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells', Biochemical and Biophysical Research Communications, vol. 385, no. 3, pp. 454-459. https://doi.org/10.1016/j.bbrc.2009.05.085
Grunt, Thomas W. ; Wagner, Renate ; Grusch, Michael ; Berger, Walter ; Singer, Christian F. ; Marian, Brigitte ; Zielinski, Christoph C. ; Lupu, Ruth. / Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. In: Biochemical and Biophysical Research Communications. 2009 ; Vol. 385, No. 3. pp. 454-459.
@article{c9432339e5a94eb69dd82ee92294fd98,
title = "Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells",
abstract = "Fatty acid synthase (FASN) represents a metabolic oncogene. It produces phospholipids for membrane microdomains that accommodate receptor tyrosine kinases including Epidermal Growth Factor-Receptor (EGFR, ErbB1) and ErbB2 (HER2/neu). FASN and ErbBs are overexpressed in ovarian cancer. We examined the effect of FASN and ErbB inhibition on A2780 and SKOV3 ovarian cancer cells. Growth assays reveal that FASN inhibitor C75 sensitizes tumor cells against anti-ErbB drugs (pelitinib [EKB-569], canertinib [CI-1033], erlotinib, cetuximab, matuzumab, trastuzumab) suggesting FASN/ErbB cooperation. qRT-PCR and Western blotting revealed that C75 represses FASN, EGFR, ErbB2, and AKT suggesting that FASN-induced membrane microdomains accommodate/stabilize ErbBs and facilitate AKT recruitment/activation. Our data indicate that AKT is crucial for ErbB/FASN interaction, AKT cross-inhibits ERK and feeds loops that boost FASN and EGFR transcription, and EGFR and ErbB2 must be co-silenced for maximal FASN downregulation. Taken together, interference with FASN and ErbB abrogates their oncogenicity and should be exploited for ovarian cancer treatment.",
keywords = "Crosstalk, EGFR, EGFR antibody, ErbB/HER, ErbB2 antibody, ErbB2/HER2, Fatty acid synthase, Ovarian cancer, Receptor tyrosine kinase, Small-molecule tyrosine kinase inhibitor",
author = "Grunt, {Thomas W.} and Renate Wagner and Michael Grusch and Walter Berger and Singer, {Christian F.} and Brigitte Marian and Zielinski, {Christoph C.} and Ruth Lupu",
year = "2009",
month = "7",
day = "31",
doi = "10.1016/j.bbrc.2009.05.085",
language = "English (US)",
volume = "385",
pages = "454--459",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells

AU - Grunt, Thomas W.

AU - Wagner, Renate

AU - Grusch, Michael

AU - Berger, Walter

AU - Singer, Christian F.

AU - Marian, Brigitte

AU - Zielinski, Christoph C.

AU - Lupu, Ruth

PY - 2009/7/31

Y1 - 2009/7/31

N2 - Fatty acid synthase (FASN) represents a metabolic oncogene. It produces phospholipids for membrane microdomains that accommodate receptor tyrosine kinases including Epidermal Growth Factor-Receptor (EGFR, ErbB1) and ErbB2 (HER2/neu). FASN and ErbBs are overexpressed in ovarian cancer. We examined the effect of FASN and ErbB inhibition on A2780 and SKOV3 ovarian cancer cells. Growth assays reveal that FASN inhibitor C75 sensitizes tumor cells against anti-ErbB drugs (pelitinib [EKB-569], canertinib [CI-1033], erlotinib, cetuximab, matuzumab, trastuzumab) suggesting FASN/ErbB cooperation. qRT-PCR and Western blotting revealed that C75 represses FASN, EGFR, ErbB2, and AKT suggesting that FASN-induced membrane microdomains accommodate/stabilize ErbBs and facilitate AKT recruitment/activation. Our data indicate that AKT is crucial for ErbB/FASN interaction, AKT cross-inhibits ERK and feeds loops that boost FASN and EGFR transcription, and EGFR and ErbB2 must be co-silenced for maximal FASN downregulation. Taken together, interference with FASN and ErbB abrogates their oncogenicity and should be exploited for ovarian cancer treatment.

AB - Fatty acid synthase (FASN) represents a metabolic oncogene. It produces phospholipids for membrane microdomains that accommodate receptor tyrosine kinases including Epidermal Growth Factor-Receptor (EGFR, ErbB1) and ErbB2 (HER2/neu). FASN and ErbBs are overexpressed in ovarian cancer. We examined the effect of FASN and ErbB inhibition on A2780 and SKOV3 ovarian cancer cells. Growth assays reveal that FASN inhibitor C75 sensitizes tumor cells against anti-ErbB drugs (pelitinib [EKB-569], canertinib [CI-1033], erlotinib, cetuximab, matuzumab, trastuzumab) suggesting FASN/ErbB cooperation. qRT-PCR and Western blotting revealed that C75 represses FASN, EGFR, ErbB2, and AKT suggesting that FASN-induced membrane microdomains accommodate/stabilize ErbBs and facilitate AKT recruitment/activation. Our data indicate that AKT is crucial for ErbB/FASN interaction, AKT cross-inhibits ERK and feeds loops that boost FASN and EGFR transcription, and EGFR and ErbB2 must be co-silenced for maximal FASN downregulation. Taken together, interference with FASN and ErbB abrogates their oncogenicity and should be exploited for ovarian cancer treatment.

KW - Crosstalk

KW - EGFR

KW - EGFR antibody

KW - ErbB/HER

KW - ErbB2 antibody

KW - ErbB2/HER2

KW - Fatty acid synthase

KW - Ovarian cancer

KW - Receptor tyrosine kinase

KW - Small-molecule tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=67349136348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349136348&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.05.085

DO - 10.1016/j.bbrc.2009.05.085

M3 - Article

C2 - 19467222

AN - SCOPUS:67349136348

VL - 385

SP - 454

EP - 459

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -